Sagimet Biosciences Inc. - SGMT
Ownership (Schedule 13D / 13G) · latest 50 filings
· Back to all files
Visible: 0
| Filed | Form | Reporting person | Percent | Shares | SEC |
|---|---|---|---|---|---|
| Aug 14, 2026 | SCHEDULE 13G | BALYASNY ASSET MANAGEMENT L.P. | 5.93% | 3,626,113 | View |
| Aug 14, 2026 | SCHEDULE 13G | BAM GP LLC | 5.93% | 3,626,113 | View |
| Aug 14, 2026 | SCHEDULE 13G | Balyasny Asset Management Holdings LP | 5.93% | 3,626,113 | View |
| Aug 14, 2026 | SCHEDULE 13G | Dames GP LLC | 5.93% | 3,626,113 | View |
| Aug 14, 2026 | SCHEDULE 13G | Dmitry Balyasny | 5.93% | 3,626,113 | View |
| Jul 30, 2026 | SCHEDULE 13G | BlackRock, Inc. | 7.8% | 4,751,186 | View |
Percent = "% of class represented by amount beneficially owned" for this reporting person in the filed 13D/13G.
Shares = reported beneficial ownership amount for the same row (not portfolio shares from 13F).
Amendments (/A) can repeat the same holder over time, so rows should not be summed.
Extraction is best-effort from filing text and can be missing or noisy; verify exact figures via the SEC link in each row.